Circulating ICAM-1, VCAM-1, E-selectin, P-selectin and TNF⍺RII in patients with coronary artery disease - 25/08/11
Abstract |
Objective |
To evaluate the relationship between the serum concentration of TNF⍺RII and some adhesion molecules (including ICAM-1, VCAM-1, P-selectin and E-selectin) and coronary artery stenosis.
Design and setting |
Observational (cross-sectional) study in a university heart hospital in Tehran, Iran.
Patients |
81 patients with angiographically proven coronary artery disease were compared with 75 individuals who had undergone coronary angiography with no significant evidence of stenosis (control subjects).
Methods |
Soluble adhesion molecules and TNF⍺RII were determined by enzyme-linked immunosorbent assay technique. sICAM-1 and sP-selectin values were significantly higher in patients with coronary artery disease than in control subjects (146 ± 38 vs. 132 ± 48 p<0.04 and 275 ± 107 vs. 241 ± 104 ng/ml p<0.04 respectively). Multiple logistic regression analysis showed sICAM-1 as an independent discriminating risk factor for coronary artery disease (p<0.03). Prediction models that incorporated sICAM-1 in addition to other established coronary risk factors were significantly better at predicting risk than the models based on the other risk factors alone. Multiple regression analysis indicated that sP-selectin levels were greater in patients with single-vessel disease than in the respective normal (p<0.01).
Conclusions |
Our findings suggest that sICAM-1 has an association with stable coronary artery disease and the evaluation of this marker may improve the coronary risk assessment in Iranian patients.
Keywords |
Atherosclerosis, Coronary heart disease, Coronary artery disease, Adhesion molecules, Tumor necrosis factor receptor 2.
Le texte complet de cet article est disponible en PDF. Funding: Tehran University |
Vol 113 - N° 2S
P. S95 - février 2004 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?